Shares of aerospace components maker Howmet Aerospace have cooled after a multi-year rally, presenting investors with a valuation puzzle. While long-term fundamentals tied to commercial aerospace and energy remain strong, a high P/E ratio raises questions about near-term risk.
A sharp downturn in cryptocurrency markets has spilled over into the stocks of major corporate holders, with MicroStrategy and BitMine leading losses as their aggressive accumulation strategies face mounting pressure.
Despite a recent 4.9% weekly pullback, shareholders of German-listed CHAPTERS Group (ETR:CHG) have seen staggering total returns exceeding 900% since 2019, fueled by explosive revenue growth. The journey highlights the potential rewards—and risks—of investing in high-growth, pre-profit companies.
Gold prices have surged past $5,500, driven by geopolitical tensions and fiscal fears. Yet, analysts caution that its reputation as a stable store of value may be overstated, pointing to inherent volatility and shifting market dynamics.
Motorpoint Group, the UK's largest independent car retailer, is showing signs of strain as its return on capital employed (ROCE) has fallen significantly over the past five years. While still above the industry average, the downward trend, coupled with rising current liabilities, suggests challenges ahead for the London-listed firm.
In a major policy shift, the CFTC under new Chairman Michael Selig is drafting a comprehensive rulebook for event contracts, aiming to bring regulatory certainty to the fast-growing prediction market industry while fostering 'permissionless innovation.'
As the broader cryptocurrency market stumbles, Sentient's SENT token has staged a remarkable 60% rally. A deep dive into on-chain and derivatives data reveals the drivers of its resilience—and the significant vulnerabilities that could threaten its gains.
Origin Bancorp (OBK) executives detailed strong profitability gains and a strategic hiring push, positioning the bank to capitalize on merger-driven market shifts and surpass $10 billion in assets.
Despite a weaker-than-expected volume environment, Norfolk Southern reported in-line cost performance for Q4 and highlighted significant strides in operational safety and efficiency. Executives pointed to a pivotal year of structural change while outlining cost and capital expenditure guidance for 2026.
Altria Group reported adjusted earnings growth and robust shareholder returns for 2025, even as it grapples with a rapidly transforming nicotine market dominated by illicit flavored vapes and intense competition in oral tobacco.
Despite a challenging price environment, Murphy Oil (MUR) reported strong operational execution for 2025 and laid out a capital plan focused on funding key international and offshore projects. While near-term production is set to dip, CEO Eric Hambly highlighted a transformative discovery in Vietnam and strategic portfolio expansion as pillars for future growth.
Meritage Homes concluded a challenging 2025, citing affordability pressures and waning buyer confidence. While maintaining a cautious stance on incentives, the homebuilder is expanding its community footprint and boosting shareholder returns, betting on long-term demographic demand.
Karman Holdings (NYSE: KRMN) is capturing Wall Street's attention as a series of bullish analyst calls, including a significant price target hike from KeyBanc, fuel its ascent. The stock's rally is tied to sustained momentum in the aerospace and defense sector, though some advise caution after its rapid gains.
Vera Therapeutics (VERA) is drawing bullish attention from Wall Street, with multiple analysts significantly raising price targets following a key competitor's FDA approval and revised revenue forecasts for its lead drug candidate.
Keefe Bruyette trimmed its price target on Pagaya Technologies (PGY) to $35, while maintaining an Outperform rating. The adjustment comes despite the AI-driven lending platform reporting robust Q3 growth and a record partner pipeline.
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.
Keefe Bruyette significantly raises its price target for Cipher Mining (CIFR), citing the company's strategic expansion into AI and high-performance computing data centers as a key growth driver.
NextPower Inc. sees its price target raised by TD Cowen following a robust third-quarter earnings beat and a landmark joint venture in Saudi Arabia, signaling growing confidence in the solar technology firm's trajectory.
